<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466180</url>
  </required_header>
  <id_info>
    <org_study_id>POSOVIR</org_study_id>
    <nct_id>NCT00466180</nct_id>
  </id_info>
  <brief_title>Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients</brief_title>
  <acronym>POSOVIR</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taking antiretrovirals once-a-day is considered the simpler way to improve adherence.
      However, it is not know if this assertion apply to patients taking their medication
      twice-a-day who change to once-a-day.

      We hypothesized that once-daily dosing improves adherence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MEMS adherence by electronic devices</measure>
    <time_frame>28-week period (randomized phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic efficacy (RNA HIV&lt;400cp/ml)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic efficacy (CD4 count cells)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance (hepatic, cutaneous, ANRS safety grade scale)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (nevirapine dosages)</measure>
  </secondary_outcome>
  <enrollment type="Actual">62</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nevirapine from twice-a-day to once-a-day</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected adults receiving antiretroviral therapy including nevirapine
             twice-a-day for at least 6 months

          -  plasma HIV RNA&lt;400 cp/ml during the previous 4 months on 2 occasions

          -  accept adherence electronic monitoring

          -  written informed consent signed

        Exclusion Criteria:

          -  asparate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5N if hepatitis
             virus B or C were negative

          -  AST or ALT&gt;1.25N if hepatitis virus B or C were positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques Parienti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <reference>
    <citation>Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008 Jul 30;3(7):e2783. doi: 10.1371/journal.pone.0002783.</citation>
    <PMID>18665246</PMID>
  </reference>
  <results_reference>
    <citation>Parienti JJ, Massari V, Reliquet V, Chaillot F, Le Moal G, Arvieux C, Vabret A, Verdon R; POSOVIR Study Group. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. AIDS. 2007 Oct 18;21(16):2217-22.</citation>
    <PMID>18090049</PMID>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <keyword>Once-a-day</keyword>
  <keyword>Adherence</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Patient noncompliance</keyword>
  <keyword>Administration and dosage</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

